

Expert opinions on benefit-risk profile and clinical use of brolucizumab

Nicholas Fung¹, FHKAM, FCOphHK, MRCS, MBChB; Danny Ng², FRCSEd, FCOphthHK; Ian Wong³, FRCOphth, MD; Raymond Wong⁴, FHKAM, MRCSEd; Pui Pui Yip⁵, FHKAM, FCOphHK; Alvin KH Kwok³, MD, PhD, FHKAM, FRCOphth, FCOphth, FCSHK, FRCSEd, PDip Epidemiology and Biostatistics, MBBS; Wai Ching Lam¹, MD, FRCSC; Timothy YY Lai², MD, FRCOphth; Ramin Khoramnia⁶, MD, FEBO

¹Department of Ophthalmology, The University of Hong Kong, Hong Kong

²Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong

³Hong Kong Sanatorium and Hospital, Hong Kong

⁴C-MER Dennis Lam and Partners Eye Center, Hong Kong

⁵Champion Eye and Refractive Surgery Centre, Hong Kong

⁶University Eye Clinic, University Hospital Heidelberg, Germany

Correspondence and reprint requests:

Dr Timothy YY Lai, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong.

Email: tyylai@cuhk.edu.hk

Abstract

Brolucizumab is a next-generation anti-vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration. It is highly potent and thus appropriate for those unresponsive to other anti-VEGF agents and those undertreated owing to the low adherence or the heavy burden of repeated injections. An expert panel of 10 retina specialists from Hong Kong and Germany convened in February 2021 to discuss the benefit-risk profile and clinical use of brolucizumab. Evidence suggests that brolucizumab provides comparable visual outcomes to aflibercept at a more relaxed injection schedule. Brolucizumab is superior to aflibercept in resolving intraretinal and subretinal fluids and decreasing disease activity. Brolucizumab is suitable for patients unresponsive to other anti-VEGF agents, especially for those with persistent intraretinal and subretinal fluids or disease activity. Injection intervals of brolucizumab can be extended to 8 to 12 weeks. However, brolucizumab has higher risk of adverse events such as intraocular inflammation, retinal vasculitis, and retinal occlusion, compared with aflibercept. Thus, regular monitoring for signs of intraocular inflammation and prompt management are important before and during treatment.

Key words: Brolucizumab; Injections, intraocular; Macular degeneration; Vascular endothelial growth factor A

Introduction

Brolucizumab is a next-generation drug for neovascular age-related macular degeneration (nAMD).¹ The general treatment goals are to maintain and improve visual acuity (VA), reduce vascular leakage, and induce regression of neovascularization.² Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents (aflibercept, bevacizumab, ranibizumab, and brolucizumab) to inhibit abnormal blood vessel development are the most effective approach (**Table 1**).²⁻⁵ Anti-VEGF agents are effective as long as strict and frequent regimens are followed, but in clinical settings undertreatment is the norm.⁶⁻¹⁰ Over 70% of patients are undertreated during their first year,¹¹ and about 60% of patients are non-adherent after 2 years.¹² The low adherence may be partly due to the burden of repeated injections. Anti-VEGF agents that can be administered at less frequent intervals are needed.¹³

Brolucizumab (Beovu, Novartis, Basel, Switzerland)¹⁴ is a single-chain antibody fragment comprising a scaffold attached to an anti-VEGF-A antibody that inhibits all isoforms of VEGF-A at a 2:1 ratio. It binds to VEGF-A isoforms and prevents their interaction with receptors VEGFR-1 and VEGFR-2, thereby suppressing endothelial cell proliferation, neovascularization, and vascular permeability.¹⁵⁻²⁰ The small molecular size of brolucizumab enables large molar dosages per injection, better penetration into ocular tissue, and greater fluid resolution.^{1,17,18} These benefits result in longer injection intervals (up to every 12 weeks).¹⁴ Furthermore, brolucizumab is easy to tolerate, as single-chain antibody fragments generally have high

stability and solubility *in vivo*.¹⁵ Trials in animal models suggest rapid systemic clearance and low exposure.^{17,18,21}

In February 2021, an expert panel comprising 10 retina specialists from public, private, and academic institutions convened to discuss evidence on the use of brolucizumab in clinical practice in Hong Kong. This study summarized the expert opinions on the benefit-risk profile and clinical use of brolucizumab.

Benefit-risk profile

In the HAWK and HARRIER phase III trials, treatment-naïve patients aged >50 years were randomly assigned to receive brolucizumab or aflibercept (HAWK: 3 mg brolucizumab [n=358], 6 mg brolucizumab [n=360], 2 mg aflibercept [n=360]; HARRIER: 6 mg brolucizumab [n=370], 2 mg aflibercept [n=369]) and were followed up for 96 weeks.^{22,23} Both trials began with a loading phase of injections at weeks 0, 4, and 8, followed by 8 weeks with no injection. The 16-week loading phase was identical between arms. Then, brolucizumab was administered every 12 weeks (or every 8 weeks in patients with disease activity), whereas aflibercept was administered every 8 weeks. Patients were assessed at weeks 16, 20, 32, and 44 for best-corrected visual acuity (BCVA), disease activity, intraretinal fluid (IRF), subretinal fluid (SRF), sub-retinal pigment epithelium (sub-RPE) fluid, and central subfield thickness (CST). Patients in the HARRIER trial were additionally assessed at weeks 28 and 40. Non-inferiority of brolucizumab against aflibercept was determined by the BCVA change from baseline to week 48, whereas safety was determined by the incidence of adverse events.





Benefits

In the HAWK and HARRIER trials, brolucizumab achieved comparable BCVA results to aflibercept despite having longer intervals (Table 2).^{22,23} Brolucizumab was superior to aflibercept in controlling disease activity and IRF/SRF. Compared with 2 mg aflibercept, 6 mg brolucizumab

resulted in about 36% less disease activity at 16 weeks after first dose, and 30% to 50% less IRF/SRF and sub-RPE fluid. Brolucizumab resulted in stronger and more consistent reduction in CST than aflibercept, with better improvement in the morphology of the macula.

In a study that pooled data from the HAWK and HARRIER trials and presented at the EURETINA 2020 Congress, brolucizumab resulted in quicker resolution of IRF/SRF than aflibercept, with lower incidence of persistent IRF/SRF over the first 12 weeks (12.5% vs 20.4%).²⁴ In patients with early persistent IRF/SRF, VA improvement was greater after brolucizumab treatment, with 8%, 48%, and 59% more patients achieving BCVA gain of ≥15 letters at 16, 48, and 96 weeks, respectively.

Retrospective reviews and case studies confirm brolucizumab’s effectiveness at suppressing disease activity (in terms of reduction in CST, fluid compartments, and large pigment epithelial detachments, and improvement in VA outcomes) in the short-term, especially for patients unresponsive to other anti-VEGF agents.²⁵⁻³⁰ In the BRAILLE chart review of 20 treatment-naïve patients and 74 recalcitrant patients who received a mean of 1.36 injections of brolucizumab and were followed up for 5 to 30 weeks, those recalcitrant patients who switched to brolucizumab had significant improvement in BCVA from 0.91 logMAR at baseline to 0.73 logMAR at final checkup, whereas all patients had an average reduction in CST of >100 µm, and >80% of treated eyes showed reduction or complete resolution of SRF, IRF, and pigment epithelial detachments.²⁷ In the REBA study of 23 treatment-naïve patients and 55 recalcitrant patients who switched to brolucizumab and were followed up for >9 months, >70% of treatment-naïve eyes had complete resolution of IRF/SRF by the end of the loading phase, whereas all recalcitrant patients who switched to brolucizumab had complete resolution of disease activity by their third brolucizumab injection.²⁹ Both groups of patients showed a gain of an average of 10 ETDRS (Early Treatment Diabetic Retinopathy Study) letters and a reduction of CST of >150 µm.

Table 1. Comparison of anti-vascular endothelial growth factor agents ¹⁶				
	Aflibercept	Bevacizumab	Ranibizumab	Brolucizumab
Molecular structure	VEGFR1/2-Fc fusion protein 	IgG1 antibody 	Antigen-binding fragment 	Single-chain antibody fragment 
Molecular weight, kDa	97-115	~149	~48	26
Clinical dose, mg	2.00	1.25	0.30-0.50	6.00
Equivalent molar dose (to aflibercept)	1.0	0.4-0.5	0.5-0.6	11.2-13.3
Injection interval	Every 8 weeks	Every 4 weeks	Every 4 weeks	Every 8 to 12 weeks

Risks

In the HAWK and HARRIER trials, over half of the patients had adverse events such as conjunctival hemorrhage, cataracts, vitreous floaters, and VA reduction, and the rate was comparable in the brolocizumab and aflibercept arms (Table 3).^{22,23} In the pooled brolocizumab group, nine patients had suspected endophthalmitis.¹ Of them, three were negative and two were positive for *Staphylococcus* or *Streptococcus mitis*, and the others were not tested or uninterpretable.

Brolocizumab is associated with greater risks of intraocular inflammation (IOI) than aflibercept.^{22,23} According to an independent safety review committee, brolocizumab carries risks of severe vision loss secondary to retinal vasculitis or retinal artery/vascular occlusion, which tend to occur in the presence of IOI.^{31,32} Thus, the consensus is to discontinue brolocizumab in any case of IOI.³¹⁻³⁴ Adverse events tend to develop within the first three injections of brolocizumab and after 3 weeks of the preceding injection, but the time from first injection to first IOI-related adverse event can

	HAWK trial			HARRIER trial		
	6 mg brolocizumab (n=360)*	2 mg aflibercept (n=360)*	p Value	6 mg brolocizumab (n=370)*	2 mg aflibercept (n=369)*	p Value
Change in best-corrected visual acuity, No. of ETDRS letters						
Week 48	6.6±0.71	6.8±0.71	<0.001	6.9±0.61	7.6±0.61	<0.001
Week 96	5.9±0.78	5.3±0.78	-	6.1±0.73	6.6±0.73	-
Disease activity						
Week 16	24.0	34.5	0.001	22.7	32.2	0.001
Presentation of intraretinal/subretinal fluid						
Week 16	33.9	52.2	0.001	29.4	45.1	<0.001
Week 48	31.2	44.6	<0.001	25.8	43.9	<0.001
Week 96	24.0	37.0	-	24.0	39.0	-
Presentation of sub-retinal pigment epithelium fluid						
Week 48	13.5	21.6	0.004	12.9	22.0	<0.001
Week 96	11.0	15.0	0.121	17.0	22.0	0.037
Change in central subfield thickness, µm						
Week 16	-161.4	-133.6	<0.001	-174.4	-134.2	<0.001
Week 48	-172.8	-143.7	0.001	-193.8	-143.9	<0.001
Week 96	-174.8	-148.7	0.012	-197.7	-155.1	<0.001

* Data are presented as least squared mean±standard error, least squared mean, or % of eyes

Adverse event	HAWK trial		HARRIER trial		Safety review committee	
	6 mg brolocizumab (n=360)	2 mg aflibercept (n=360)	6 mg brolocizumab (n=370)	2 mg aflibercept (n=369)	Brolocizumab (n=1088)	Aflibercept (n=729)
No. (%) of patients or % of patients						
Ocular adverse event at 96 weeks	220 (61.1)	201 (55.8)	174 (47.0)	176 (47.7)	-	-
Serious ocular adverse event at 96 weeks	12 (3.3)	5 (1.4)	13 (3.5)	6 (1.6)	-	-
Intraocular inflammation	17 (4.7)	2 (0.6)	3 (0.8)	4 (1.1)	50 (4.6)	8 (1.1)
Retinal vasculitis	-	-	-	-	36 (3.3)	-
Retinal artery and vascular occlusion	4 (1.1)	0 (0.0)	2 (0.5)	1 (0.3)	23 (2.1)	-
Endophthalmitis	4 (1.1)	0 (0.0)	1 (0.3)	1 (0.3)	9 (<0.1)	-
Loss of ≥15 ETDRS letters at 96 weeks	8.1	7.4	7.1	7.5	7.4 (at 48 weeks)	7.7 (at 48 weeks)

be up to 18 months.³⁵ The mechanism of brolocizumab-related adverse events may be associated with a delayed hypersensitivity response, impurities in the serum, or excessive VEGF inhibition.^{36,37}

Intraocular inflammation

The safety review committee identified 50 definite or probable cases of IOI in all brolocizumab-treated eyes (n=1088) in the HAWK and HARRIER trials, compared with eight cases in the aflibercept arms (Table 3).³¹ IOI tends to occur early in treatment, with about 50% and 80% occurring within 3 and 12 months, respectively; earlier occurrence is associated with greater risk of vision loss.^{1,31,32,35} According to medical claim data in the IRIS Registry and Komodo study, the incidence of IOI within 6 months of the first brolocizumab injection was 2.4%, with prior IOI or retinal occlusion being a risk factor.³⁸ Most IOI cases in the HAWK and HARRIER trials were mild to moderate and were resolved without sequelae.^{1,35} Most severe IOI cases did not result in diminished VA outcomes; of 49 patients with severe IOI, only 14 had loss of BCVA, whereas 23 had improved and 12 had stable BCVA.¹

IOI may precede retinal vasculitis or retinal occlusion by 16 to 171 days.³⁵ Uveitis, iritis, vitritis, and iridocyclitis are the most common initial presentations of IOI before retinal vasculitis or retinal occlusion.³⁵ Signs of IOI include inflammatory cells in anterior and/or posterior segments, vitreous cells or opacities, non-granulomatous keratic precipitates, conjunctival injection, Descemet's membrane, and corneal edema.³⁵

The incidence of IOI appeared to be higher in Japanese patients.^{39,40} According to the Japan AMD Research Consortium study of 127 eyes treated with brolocizumab, the rate of IOI during the first 6 months was notably high at 9% to 10%,³⁹ which was nevertheless lower than the 13% reported by the safety review committee for Japanese patients in the HAWK trial. In a post-hoc analysis of Japanese patients with polypoidal choroidal vasculopathy in the HAWK trial, the rate of IOI was higher in brolocizumab users than aflibercept users (15% vs 0%), but the sample size was too small to perform post-hoc statistical analysis.⁴⁰ Ophthalmologists should be aware that Japanese populations may be at greater risk of IOI, but the evidence remains inconclusive.

Retinal vasculitis, retinal occlusion, and vision loss

Of the 50 eyes with IOI identified by the safety review committee, 36 involved retinal vasculitis and 23 involved retinal vasculitis and retinal occlusion (Table 3).^{31,32} Nonetheless, the overall risk of moderate or severe vision loss was <1%, which is similar to that for aflibercept. For all vision loss cases, brolocizumab was associated with a 7.4% risk of vision loss within 2 years, compared with 7.7% for aflibercept. Most vision loss cases were caused by the degenerative nature of nAMD and were not drug-related.¹

Records for adverse events associated with brolocizumab are submitted by practitioners worldwide to the website: brolocizumab.info. From October 2019 to September 2021, for every 10000 injections, there were 5.4 cases of retinal vasculitis, 3.3 cases of retinal occlusion, and 7.0 cases of both (15.7 cases overall), of them 4.9 cases were severe vision loss.

Recommendations

Brolocizumab is comparable with aflibercept in terms of VA outcomes but has a more relaxed treatment schedule that may facilitate adherence. Brolocizumab achieves better outcome in terms of resolving fluids, controlling disease activity, and improving macula morphology. Brolocizumab-associated adverse events are rare. Nevertheless, patients should be regularly assessed for IOI signs after administering brolocizumab, as onset may be nonspecific and may develop weeks after injection. Early diagnosis is important for timely intervention, treatment, and monitoring. Brolocizumab is contraindicated when IOI is suspected.³⁵ Measures to reduce risk are the same as those for other anti-VEGF agents. It is important to avoid injecting any anti-VEGF agent into an inflamed eye. Ophthalmologists should arrange the times of assessment and injection close to each other and follow up on any reports of suspicious symptoms. A management plan for the clinical use of brolocizumab is shown in the Figure.

Patient selection

Brolocizumab can be used in both treatment-naïve patients and patients with ongoing anti-VEGF therapy. Currently, brolocizumab is mostly used in patients with ongoing anti-VEGF therapy. It is advisable to keep using the existing agents if effective; there is no need to switch to brolocizumab if the injection schedule can be extended to at least every 8 weeks. Brolocizumab should be avoided in patients with a history of IOI or retinal occlusion in the preceding 12 months. Brolocizumab can be considered in treatment-naïve patients with persistent SRF and sub-RPE fluid (eg, polypoidal choroidal vasculopathy). Brolocizumab can also be considered in patients with difficulty controlling disease activity or improving macula morphology and in patients struggling to extend treatment interval beyond 4 to 6 weeks.^{22,23} Brolocizumab is appropriate in patients unresponsive to other anti-VEGF agents including those with polypoidal choroidal vasculopathy or pigment epithelial detachments.^{25,40} Guidelines are helpful to avoid selecting patients at risk of adverse events and to provide treatment approaches.^{33,34} Screening patients for IOI risks may help alleviate concerns.

Monitoring

Pre-existing IOI and signs of inflammation should be ruled out with a dilated-pupil fundus examination before the loading injection. When switching to brolocizumab, patients should be closely monitored for any manifestation of drug-associated IOI during the initial 6 months and even 18 months, as IOI can develop up to 18 months from the first injection.³⁵ Complete ophthalmic examination with

be evaluated for underlying systemic or infectious diseases that may cause IOI such as giant cell arteritis and collagen vascular diseases. Optical coherence tomography and wide-field or peripheral-field fluorescein angiography should be used for diagnosing. The diagnosis of retinal vasculitis should be confirmed by evaluation of vessel involvement. Treatment regimen should follow a gradient of intensive corticosteroids based on the severity of IOI and/or vascular involvement. Immunomodulating therapy, vitrectomy, and pan-retinal photocoagulation are alternative treatment options, especially for steroid-intolerant patients. If there is no vascular involvement and the IOI is mild, intensive topical corticosteroids can be used. Close monitoring and gradual tapering of dosage can be considered if conditions improve. Patients who fail to respond or worsen should be offered systemic and/or intravitreal corticosteroids. For retinal vasculitis, retinal occlusion, and moderate-to-severe IOI, immediate systemic and intravitreal corticosteroids supplemented with topical corticosteroids should be used. Other adjunctive therapies include corticosteroid implants and/or subtenon steroid injections.

Conclusion

IRF and SRF are pathological features of nAMD, and their resolution is the key to achieve good BCVA outcomes and to extend treatment intervals. However, unresolved IRF/SRF and non-adherence to the treatment schedule may result in vision loss. Moreover, the high frequency of injections burdens healthcare providers and patients. Brolucizumab (6 mg) is effective to improve vision, resolve IRF/SRF, and extend treatment intervals to ≥ 12 weeks. Brolucizumab has a well-tolerated safety profile. Its rate of vision loss is comparable to that of aflibercept. A safe and effective management plan should involve proper patient selection, regular monitoring (especially in the first 18 months of therapy), and prompt intensive treatment of adverse events.

Contributors

All authors designed the study, acquired the data, analyzed the data, drafted the manuscript, and critically revised the

manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

Conflicts of interest

NF is a principal investigator in partnerships with Alcon, Allergan, Bayer, Chengdu Kanghong Pharm, Novartis, and Roche, and has received honoraria and research grant from them. RW has received honoraria from Bayer, Novartis, and Roche. WCL has received research grant and honoraria from Alcon and Bayer and honoraria from Allergan and Novartis. TL has received honoraria and grant support from Allergan, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotech, Novartis, and Roche. RK has received grant and financial support from Alimera, Allergan, Bayer, Chengdu Kanghong, Novartis, and Roche. All other authors have received honoraria from Novartis.

Funding/support

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. However, honorariums were provided by Novartis Pharmaceuticals (Hong Kong) to panel experts in relation to this meeting. The funder had no role in study design or interpretation or in manuscript preparation other than providing fund for the medical writer.

Data availability

All data generated or analyzed during the present study are available from the corresponding author on reasonable request.

Acknowledgments

Medical writing assistance by Stephen Heap of MIMS (Hong Kong) was funded by Novartis Pharmaceuticals (Hong Kong) and complied with Good Publication Practice 3 ethical guidelines.

References

1. Novartis Pharma AG. Core Submission Dossier PTJA09. Available from: <https://www.eunetha.eu/wp-content/uploads/2020/03/PTJA09-brolucizumab-Core-Submission-Dossier-by-Novartis-v1.0.pdf>.
2. Flaxel CJ, Adelman RA, Bailey ST, et al. Age-Related Macular Degeneration Preferred Practice Pattern®. *Ophthalmology* 2020;127:P1-P65.
3. Regeneron. Eylea ® prescribing information. Available from: https://www.regeneron.com/downloads/eylea_fpi.pdf.
4. Genentech. Lucentis ® prescribing information. Available from: https://www.gene.com/download/pdf/lucentis_prescribing.pdf.
5. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. *Ann Pharmacother* 2007;41:614-25.
6. Kiss S, Liu Y, Brown J, et al. Clinical monitoring of patients with age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. *Ophthalmic Surg Lasers Imaging Retina* 2014;45:285-91.
7. Boulanger-Scemama E, Querques G, About F, et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. *J Fr Ophtalmol* 2015;38:620-7.
8. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor

- therapy for wet age-related macular degeneration. *Br J Ophthalmol* 2015;99:220-6.
9. Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. *Retina* 2016;36:1418-31.
 10. Ehlken C, Helms M, Böhringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. *Clin Ophthalmol* 2017;12:13-20.
 11. MacCumber MW. Real-world injection intervals in wet AMD. *Retina Today* 2020:20-2.
 12. Buckle M, Donachie PH, Johnston RL. Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK. *Br J Ophthalmol* 2016;100:240-5.
 13. Freund KB, Mrejen S, Gallego-Pinazo R. An update on the pharmacotherapy of neovascular age-related macular degeneration. *Expert Opin Pharmacother* 2013;14:1017-28.
 14. Novartis. BEOVU @ prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s0001bl.pdf.
 15. Nelson AL. Antibody fragments: hope and hype. *MAbs* 2010;2:77-83.
 16. Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolicizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. *Ophthalmologica* 2021;244:93-101.
 17. Gaudreault J, Gunde T, Floyd HS, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. *Invest Ophthalmol Vis Sci* 2012;53:3025.
 18. Tietz J, Spohn G, Schmid G, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor A for the treatment of retinal disorders. *Invest Ophthalmol Vis Sci* 2015;56:1501.
 19. Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. *Ophthalmology* 2016;123:1080-9.
 20. Szabó E, Phillips DJ, Droste M, et al. Antitumor activity of DLX1008, an anti-VEGFA antibody fragment with low picomolar affinity, in human glioma models. *J Pharmacol Exp Ther* 2018;365:422-9.
 21. Nimz EL, Van't Land CW, Yáñez JA, Chastain JE. Intraocular and systemic pharmacokinetics of brolicizumab (RTH258) in nonhuman primates. *Invest Ophthalmol Vis Sci* 2016;57:4996.
 22. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolicizumab for neovascular age-related macular degeneration. *Ophthalmology* 2020;127:72-84.
 23. Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolicizumab for neovascular age-related macular degeneration. *Ophthalmology* 2021;128:89-99.
 24. Lally D. An assessment of BCVA and CST outcomes with brolicizumab and aflibercept in patients with early persistent retinal fluid: 96 week pooled data from HAWK and HARRIER. Presented at: EURETINA 2020 congress. October 2020.
 25. Sharma A, Kumar N, Parachuri N, et al. Brolicizumab—early real-world experience: BREW study. *Eye (Lond)* 2021;35:1045-7.
 26. Bulirsch LM, Saßmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolicizumab for neovascular AMD: SHIFT study. *Br J Ophthalmol* 2022;106:1288-94.
 27. Chakraborty D, Maiti A, Sheth JU, et al. Brolicizumab in neovascular age-related macular degeneration: Indian real-world experience: the BRAILLE study. *Clin Ophthalmol* 2021;15:3787-95.
 28. Panigrahi PK. A case of recalcitrant neovascular wet age-related macular degeneration treated with intravitreal brolicizumab. *Photodiagnosis Photodyn Ther* 2021;35:102450.
 29. Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolicizumab in wet age-related macular degeneration: the REBA study. *J Clin Med* 2021;10:2758.
 30. Avaylon J, Lee S, Gallemore RP. Case series on initial responses to intravitreal brolicizumab in patients with recalcitrant chronic wet age-related macular degeneration. *Int Med Case Rep J* 2020;13:145-52.
 31. Member update: Novartis-appointed safety review committee reports initial brolicizumab findings. Available from: https://www.brolicizumab.info/sites/brolicizumab_info/files/2020-07/ASRS_SRC_report.pdf.
 32. Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolicizumab: post hoc review of HAWK and HARRIER. *Ophthalmology* 2021;128:1050-9.
 33. Bauml CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolicizumab treatment. *Ophthalmol Retina* 2021;5:519-27.
 34. Sharma A, Kumar N, Parachuri N, et al. Brolicizumab; foreseeable workflow in the current scenario. *Eye (Lond)* 2021;35:1548-50.
 35. Khoramnia R, Figueroa MS, Hattenbach LO, et al. Manifestations of intraocular inflammation over time in patients on brolicizumab for neovascular AMD. *Graefes Arch Clin Exp Ophthalmol* 2022;260:1843-56.
 36. Bauml CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolicizumab. *Ophthalmology* 2020;127:1345-59.
 37. Haug SJ, Hien DL, Uludag G, et al. Retinal arterial occlusive vasculitis following intravitreal brolicizumab administration. *Am J Ophthalmol Case Rep* 2020;18:100680.
 38. Khanani AM, Zarbin MA, Barakat MR, et al. Safety outcomes of brolicizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map. *JAMA Ophthalmol* 2022;140:20-28.
 39. Maruko I, Okada AA, Iida T, et al. Brolicizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. *Graefes Arch Clin Exp Ophthalmol* 2021;259:2857-9.
 40. Ogura Y, Jaffe GJ, Cheung CMG, et al. Efficacy and safety of brolicizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. *Br J Ophthalmol* 2022;106:994-9.